1-8 of 8
Liwei Wang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial

Clinical Trials & Observations
Joshua D. Brody, Judit Meszaros Jørgensen, Dr, David Belada, Régis Costello, Marek Trněný, Umberto Vitolo, David John Lewis, Yasmin H. Karimi, Anna Sureda, Marc Andre, Björn E. Wahlin, Pieternella J. Lugtenburg, Tony Jiang, Kubra Karagoz, Andrew J Steele, Aqeel Abbas, Liwei Wang, Malene Risum, Raul Cordoba
Journal: Blood
Blood blood.2024026830.
https://doi.org/10.1182/blood.2024026830
Published: 2025
Includes: Supplemental data
Journal Articles

Fixed-Duration Epcoritamab + R 2 Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial

Lorenzo Falchi, Anna Sureda Balari, Sirpa Leppä, Joost S.P. Vermaat, Marcel Nijland, Jacob Haaber Christensen, Sven de Vos, Harald Holte, Reid W. Merryman, Pieternella Lugtenburg, Pau Abrisqueta Costa, Kim Linton, Gauri Sunkersett, Christopher Morehouse, Andrew J. Steele, Jennifer Marek, Liwei Wang, Daniela Hoehn, Martin Hutchings, David Belada
Journal: Blood
Blood (2024) 144 (Supplement 1): 342.
https://doi.org/10.1182/blood-2024-200262
Published: 2024
Journal Articles

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

Clinical Trials & Observations
Adam D. Cohen, María-Victoria Mateos, Yael C. Cohen, Paula Rodriguez-Otero, Bruno Paiva, Niels W. C. J. van de Donk, Thomas Martin, Attaya Suvannasankha, Kevin C. De Braganca, Christina Corsale, Jordan M. Schecter, Helen Varsos, William Deraedt, Liwei Wang, Martin Vogel, Tito Roccia, Xiaoying Xu, Pankaj Mistry, Enrique Zudaire, Muhammad Akram, Tonia Nesheiwat, Lida Pacaud, Irit Avivi, Jesus San-Miguel
Journal: Blood
Blood (2023) 141 (3): 219–230.
https://doi.org/10.1182/blood.2022015526
Published: 2023
Includes: Supplemental data
Journal Articles

Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R 2 ) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial

Lorenzo Falchi, Lori A. Leslie, David Belada, Katerina Kopeckova, Fritz Offner, Joshua Brody, Miguel Canales, Alejandro Martín García-Sancho, Marcel Nijland, P-O Andersson, Farrukh T. Awan, Jacob Haaber Christensen, Kristina Drott, Mats Hellström, Catharina Lewerin, Mayur Narkhede, Sylvia Snauwaert, Björn E Wahlin, Ali Rana, Aqeel Abbas, Liwei Wang, Minh Dinh, Joost S.P. Vermaat, Pau Abrisqueta
Journal: Blood
Blood (2022) 140 (Supplement 1): 1471–1473.
https://doi.org/10.1182/blood-2022-158232
Published: 2022
Journal Articles

Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update

Lorenzo Falchi, Pau Abrisqueta, Marcel Nijland, Sirpa Leppä, Martin Hutchings, Harald Holte, Reid W Merryman, Pieternella Lugtenburg, Sven de Vos, Chan Y. Cheah, Jacob Haaber Christensen, Luca Arcaini, Kristina Drott, Mats Hellström, Lori A. Leslie, Umberto Vitolo, Ali Rana, Aqeel Abbas, Liwei Wang, Minh Dinh, David Belada
Journal: Blood
Blood (2022) 140 (Supplement 1): 1464–1466.
https://doi.org/10.1182/blood-2022-158203
Published: 2022
Journal Articles

Subcutaneous Epcoritamab + R-Dhax/C in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Eligible for Autologous Stem Cell Transplant: Updated Phase 1/2 Results

Pau Abrisqueta, Raul Cordoba, Lorenzo Falchi, Sven de Vos, Marcel Nijland, Fritz Offner, Jun Wu, Irina Bykhovski, Liwei Wang, Ali Rana, Tycel Phillips
Journal: Blood
Blood (2022) 140 (Supplement 1): 1068–1069.
https://doi.org/10.1182/blood-2022-158278
Published: 2022
Journal Articles

Efficacy and Safety of Ciltacabtagene Autoleucel (Cilta-cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Lenalidomide-Refractory Patients with Progressive Multiple Myeloma after 1-3 Prior Lines of Therapy: Updated Results from CARTITUDE-2

Yael C. Cohen, Adam D Cohen, Michel Delforge, Jens Hillengass, Hartmut Goldschmidt, Katja Weisel, Marc-Steffen Raab, Christof Scheid, Jordan M. Schecter, Kevin C. De Braganca, Helen Varsos, Tzu-min Yeh, Liwei Wang, Martin Vogel, Christina Corsale, Muhammad Akram, Lida Pacaud, Tonia Nesheiwat, Mounzer Agha, Hermann Einsele
Journal: Blood
Blood (2021) 138 (Supplement 1): 3866.
https://doi.org/10.1182/blood-2021-146072
Published: 2021
Journal Articles

CARTITUDE-2: Efficacy and Safety of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell Therapy, in Patients with Multiple Myeloma and Early Relapse after Initial Therapy

Niels W.C.J. Van de Donk, Michel Delforge, Mounzer Agha, Adam D Cohen, Yael C Cohen, Jens Hillengass, Sebastien Anguille, Tessa Kerre, Wilfried Roeloffzen, Jordan M. Schecter, Kevin C. De Braganca, Helen Varsos, Liwei Wang, Martin Vogel, Enrique Zudaire, Christina Corsale, Muhammad Akram, Dong Geng, Tonia Nesheiwat, Lida Pacaud, Pieter Sonneveld, Sonja Zweegman
Journal: Blood
Blood (2021) 138 (Supplement 1): 2910.
https://doi.org/10.1182/blood-2021-146074
Published: 2021